Finally, disease-modifying and suppressive inflammatory effects of targeting β2- and α-ARs strongly support that combined AR-targeted therapies have great therapeutic potential to reduce joint destruction and inflammation and complications of RA, like cachexia. Here, AARS1 is linked to Cachexia.